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Abstract
The two migration inhibitory factor- (MIF)-related protein-8 (MRP8; S100A8) and MRP14 (S100A9) are two calcium-
binding proteins of the S100 family. These proteins are expressed during myeloid differentiation, are abundant in
granulocytes and monocytes, and form a heterodimeric complex in a Ca2-dependent manner. Phagocytes expressing MRP8
and MRP14 belong to the early infiltrating cells and dominate acute inflammatory lesions. In addition, elevated serum levels
of MRP8 and MRP14 have been found in patients suffering from a number of inflammatory disorders including cystic
fibrosis, rheumatoid arthritis, and chronic bronchitis, suggesting conceivable extracellular roles for these proteins. Although
a number of possible functions for MRP8/14 have been proposed, the biological function still remains unclear. This review
addresses recent developments regarding the MRP14-mediated promotion of leukocyte-endothelial cell-interactions and the
characterization of MRP8/14 heterodimers as a fatty acid binding protein complex. In view of the current knowledge, the
authors will hypothesize that MRP8 and MRP14 play an important role in leukocyte trafficking, but do not affect neutrophil
effector functions. ß 1998 Elsevier Science B.V. All rights reserved.
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1. Introduction
Calcium has been implicated as a regulatory ion in
a variety of cellular processes such as muscle contrac-
tion, secretion, adhesion, synaptic transmission, cell-
cycle progression, and di¡erentiation. The calcium-
coupled responses consist of three major steps: (1) the
binding of ligands to cell surface receptors results
in a rise of intracellular calcium concentration;
(2) calcium binds to intracellular calcium-binding
proteins containing the EF-hand motif which then
interact with target proteins such as protein kinases,
protein phosphates, and ion-transporting proteins;
and (3) these target proteins are part of the down-
stream signaling elements which result in the com-
plex activation of transcription factors responsible
for the cellular response to the stimulus.
The rise in intracellular calcium concentration is
transduced by the ‘activation’ of calcium-binding
proteins. There are four major classes of intracellular
calcium-binding proteins distinct from phospholipase
C and protein kinase C. These are (1) the calcium-
modulated signaling proteins of the EF-hand family,
(2) the calcium- and phospholipid-binding proteins
of the annexin family, (3) a diverse group of cyto-
skeletal calcium-binding and actin-modulating pro-
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teins, and (4) the high-capacity calcium storage pro-
teins found in the microsomal compartment of the
ER.
This review addresses recent developments regard-
ing two low-molecular-mass calcium-binding pro-
teins containing EF-hand motifs, MRP8 and
MRP14, which belong to the S100 protein family
(for reviews see [1^3]). We will brie£y review the old-
er literature regarding the involvement of MRP8 and
MRP14 in in£ammatory diseases and discuss in more
detail their protein and gene structure, their hetero-
dimer formation, their restricted cellular expression,
and their calcium-induced movement to cellular com-
partments as well as their release from cells. Finally,
we will summarize intra- and extracellular functions
of MRP8 and MRP14. In view of the current knowl-
edge some attention will be focused on the e¡ect
MRP8 and MRP14 have on lipid metabolism, and
we will hypothesize that MRP8 and MRP14 have a
regulatory role in neutrophil adhesion to endothe-
lium without further neutrophil activation.
2. MRP8 and MRP14 belong to the S100 protein
family
Polymorphonuclear leukocytes (PMN) are the pre-
dominant cell type present in areas of acute in£am-
mation. They continuously circulate in the body,
screening for the presence of altered cells, infecting
microbes and foreign antigens. Two proteins abun-
dant in monocytes and granulocytes were initially
puri¢ed using the monoclonal antibody 1C5, which
was directed against the macrophage migration in-
hibitory factor (MIF). Although the proteins them-
selves did not exhibit any migration inhibitory prop-
erties they were called MIF-related proteins (MRP)
(for a review see [4]). Computer-based homology
search revealed that MRP8 is identical to the se-
quence of the cystic ¢brosis (CF) antigen with one
exception. The sequence of MRP8 cDNA contains
an additional G residue in position 292 which shifts
the reading frame of the last 15 amino acids. MRP8
is also referred by other names such as L1 light chain
antigen, p8 and calgranulin A, and MRP14, corre-
spondingly, as L1 heavy chain antigen, p14, and cal-
granulin B [5^7].
The genes encoding the S100 family were found to
be localized in a cluster on human chromosome
1q21, and several murine homologues have been lo-
calized to a synthenic region on mouse chromosome
3. Therefore, it is suggested that the clustered organ-
ization of these S100 genes has been conserved dur-
ing evolution. Heizmann’s group proposed a new
logical nomenclature for these genes, which is based
on the physical arrangement on the chromosome
1q21 [8]. According to this nomenclature, MRP8 is
referred to as S100A8, and MRP14 as S100A9, re-
spectively. Heizmann and co-workers have recently
identi¢ed two novel calcium-binding proteins belong-
ing to the S100 protein family, S100A12 and
S100A13. The latter colocalizes with S100A1 on the
cluster, whereas S100A12 is localized between the
genes S100A8 and S100A9 [9,10].
It is worth mentioning that the ¢rst link between
S100 family members and a speci¢c disease was made
for MRP8 and MRP14. It was speculated for con-
siderable time that these two proteins could represent
the proteins responsible for cystic ¢brosis, a specula-
tion now superseded by the cloning of the gene en-
coding the membrane protein cystic ¢brosis conduct-
ance regulator (CFTR). Nevertheless, it has been
shown that MRP8- and MRP14-expressing cells be-
long to the early in¢ltrating cells and dominate acute
in£ammatory lesions [11]. Phagocytes expressing
MRP8 and MRP14 are found in a variety of in£am-
matory conditions, including rheumatoid arthritis,
allograft rejections, and in£ammatory bowel and
lung diseases [12,13]. In£ammatory disorders, such
as chronic bronchitis, cystic ¢brosis, and rheumatoid
arthritis, are associated with elevated plasma levels of
MRP8/14 [14,15]. Therefore, MRP8 and MRP14 are
widely used as marker proteins for activated or re-
cruited phagocytes. Although there are a number of
hypotheses, the exact functions of both proteins
remain unknown. Whether these proteins contribute
to leukocyte tra⁄cking or may have a propagat-
ing role in in£ammatory responses, remains to be
elucidated.
3. MRP8 and MRP14 share structural homology with
S100 proteins
Kyte and Doolittle hydropathy analysis indicates
that MRP8 and MRP14 have hydropathic pro¢les
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similar to other S100 proteins known to dimerize.
Both MRP8 and MRP14 possess the same hydro-
phobic N- and C-terminal regions and hydrophilic
EF-hands as calcyclin and S100L. These results imply
that both MRP8 and MRP14 share structural ho-
mology with other S100 proteins.
MRP8 and MRP14 are composed of two distinct
helix^loop^helix motifs (EF-hand) £anked by hydro-
phobic regions at either terminus and separated by a
central hinge region (Fig. 1). The C-terminal EF-
hand has a higher a⁄nity for Ca2 and encompasses
12 amino acids, whereas the N-terminal Ca2-bind-
ing loop is formed by 14 amino acids. Alignment of
the calcium-binding loops of MRP8 and MRP14
with other members of the S100 protein family
show that MRP14 contains the conserved sequence
determinants necessary for calcium binding in sites I
and II which are found in other S100 proteins.
MRP8 also has the standard binding loop in site II
but a signi¢cant Glu33CAsp33 substitution at posi-
tion 14 of the calcium-binding loop in the N-terminal
pseudo EF-hand. Since this residue is known to play
an important role in calcium binding and is highly
conserved within this position in S100 proteins [16],
it is concluded that the N-terminal EF-hand of
MRP8 is not likely to bind calcium with appreciable
a⁄nity.
In addition to the binding of Ca2, human MRP14
has also been shown to bind Zn2. However, the
Zn2 binding sites are apparently distinct and inde-
pendent of the two Ca2 binding domains [17].
The exon/intron structures of the MRP8 and
MRP14 genes are similar to most other S100 genes
[18]. The MRP genes consist of three exons with
di¡erent lengths (33, 164, and 211 bp for MRP8
and 28, 165, and 380 bp for MRP14) which are sep-
arated by two introns of di¡erent lengths (484 and
150 bp for MRP8, 292 bp and V2 kb for MRP14).
In each gene, exon 1 encodes the untranslated region.
The proteins are encoded by sequences in exon 2,
encoding the N-terminal 47 amino acids of MRP8
and 50 amino acids of MRP14, respectively. The
exon 3 codes for the C-terminal 46 amino aids of
MRP8 and 64 amino acids of MRP14, respectively
(Fig. 2).
The sequence of human MRP8 cDNA has an open
reading frame of 279 nucleotides predicting a protein
of 93 amino acids and a calculated Mr of 10 835,
whereas the human MRP14 contains an open read-
ing frame of 352 nucleotides predicting a protein of
114 amino acids and a calculated Mr of 13 242 [7].
Both human MRP8 and MRP14 contain a single
cysteine residue, they have no signal or membrane
anchor sequence, and they both lack consensus se-
quences for N-linked glycosylation. The predicted
amino acid sequences of hMRP8 and hMRP14 are
highly homologous to each other, and also similar to
the S100 proteins such as S100K, S100L, intestinal
Fig. 1. Structural domains within MRP8 and MRP14. Amino acid sequences of human MRP8 and MRP14 were obtained from
SWISS-PROT protein sequence data base, and the alignment was performed with the help of LALIGN. Identical residues are indi-
cated by ‘:’, and homologous residues are indicated by ‘.’. Both proteins share 28.3% identity in a 92-amino-acid overlap, and a
72.8% homology, respectively. Helical elements are predicted with the help of NNPREDICT, and they are indicated by blank boxes.
The calcium binding loop I (12 aa EF-hand) and II (14 aa EF-hand) are indicated by gray boxes. Hydrophobic residues critical for
formation of the dimer interface were obtained from Potts et al. [26], and they are indicated by dark gray boxes.
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calcium-binding protein, calcyclin, pro¢llagrin, and
calvasculin.
Human MRP14 has several posttranslational mod-
i¢cations. Matrix-assisted laser desorption-ionisation
(MALDI) mass spectroscopy reveals the existence of
two forms of human MRP14 with molecular masses
of 12 693 þ 3 Da and 13 157 þ 3 Da, representing a
full-length and a N-truncated form. The full-length
form of MRP14 lacks the ¢rst Met, and Thr at posi-
tion 2 is acetylated leading to a calculated molecular
mass of 13 154 Da. The N-truncated isoform results
from alternative translation, starting with the Met at
position 5. Posttranslational removing of Met at po-
sition 5 and consequent acetylation of Ser at position
6 leads to a calculated molecular mass of 12 690 Da
([19]; T. Vogl, unpublished observation). However, it
is worth to note that the truncated MRP14 does not
contain a cysteine residue. The threonine at position
113 can be phosphorylated upon PMN activation,
and phosphorylation of this residue is speci¢cally
regulated by the Ca2-ionophore, ionomycin. How-
ever, the protein kinase that phosphorylates MRP14
has not yet been identi¢ed [20]. Whether MRP8 also
is phosphorylated is still a point of controversy
[21,22].
Interestingly, the C-terminal region of human
MRP14 has sequence identity with a factor found
to have neutrophil immobilizing activity, called
NIF [20,23]. Whether the penultimate amino acid
of MRP14, Thr113, is involved in the proposed NIF
activity thereby participating in immobilizing mye-
loid cells at the endothelial surface and facilitating
their movement into tissues, remains unknown.
4. MRP8 and MRP14 form a heterodimer
The calcium-induced formation of stable hetero-
dimers of MRP8 and MRP14 (as well as higher or-
der species) in vivo was initially demonstrated by
chemical cross-linking and subsequent isolation of
the complexes by immunoa⁄nity chromatography
[19]. Further extensive biophysical characterization,
including CD-, £uorescence- and NMR-spectro-
scopy, have con¢rmed this result. Analysis by
NMR-spectroscopy revealed that calcium binding
to the MRP8/14 heterodimer results in structural
changes in the linker, helix 3 and second calcium-
binding loop regions. These conformational changes
lead to the exposure of hydrophobic surfaces upon
calcium binding that may allow interaction with the
target protein. A model for target protein binding to
calcium-activated S100 dimers has been proposed by
Groves et al. [24]. The calcium binding to S100 dimer
results in structural changes in the linker, helix 3 and
second calcium-binding loop regions. A number of
target proteins have been identi¢ed, and the confor-
mational change occurring upon Ca2 binding has
been demonstrated for a number of S100 proteins
[2,8,25]. In addition, it has been shown that disul¢de
bridges are not involved in the in vitro formation of
the dimeric (and not higher order) species, and once
the protein complex is formed, it is una¡ected by the
addition of EDTA.
The S100 proteins share signi¢cant amino acid
similarity in the N- and C-terminal regions contain-
ing the hydrophobic regions and the EF-hand motifs.
Areas of greatest divergence are found in the hinge
Fig. 2. Exon/intron structures of the MRP8 and MRP14 genes
[18].
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region. These two regions may therefore be respon-
sible for the speci¢c interaction with target proteins
[1].
Chazin and co-workers have determined the three-
dimensional structure of the S100 protein calcyclin in
solution in the apo state by NMR-spectroscopy [26].
From these data they have concluded that the dimer
interface of the calcyclin homodimer is primarily
mediated by hydrophobic interactions between side
chains. The helices 4 and 4P form the bulk of the
dimer interface. They are in contact over almost their
entire length (Phe70^Met82), packed antiparallel to
each other. Residues at the C-terminus of helices 1
and 1P also contribute to the dimer interface, making
contacts with both helices 4 and 4P, thereby forming
a hydrophobic core. By computer-based homology
search within the S100 protein family they predicted
the residues Ile13, Tyr16 (located in helix 1), Phe68,
Val80 (located in helix 4), and Ser86 (located in the C-
terminal region) of MRP8, and Ile16, Phe19, Phe76,
Trp88, and Met94 within the amino acid sequences of
MRP8 and MRP14 as critical for the heterodimer
formation (Fig. 1). The involvement of these critical
residues to the heterodimer formation of MRP8 and
MRP14 is currently under investigation in our labo-
ratory using two-hybrid system and site-directed mu-
tagenesis.
Although the general consensus is that the protein
function is dependent on heterodimer formation,
studies also support the possibility that these proteins
may have individual functions. For example, MRP14
is shown to be expressed independently of MRP8 in
acutely in£amed tissues [7,27]. The NMR-analysis of
both MRP8 and MRP14 homodimers provides evi-
dence that in contrast to MRP14 homodimers, the
MRP8 homodimers are unable to form stable well-
packed molecules. Therefore, the authors have sug-
gested that MRP14 alone, but not MRP8 alone, has
biologically relevant activity in speci¢c in£ammatory
events [28].
5. MRP8 and MRP14 expression is primarily
restricted to cells of myeloid lineage
Like other S100 proteins, MRP8 and MRP14 are
also expressed in a tissue/cell-speci¢c manner. Their
expression appears to be restricted to a speci¢c stage
of myeloid di¡erentiation, because both proteins are
expressed in circulating neutrophils and monocytes,
but not in normal tissue macrophages. They are ab-
sent in lymphocytes, and in peripheral blood mono-
cytes their expression is down-regulated during ma-
turation to macrophages [11,18].
However, several studies have demonstrated that
in in£ammatory diseases MRP8 and MRP14 are in-
dependently expressed, and that the expression pat-
tern of the proteins depends on acute and chronic
in£ammatory conditions [7,11,27,29,30]. The other
tissue type found to express MRP8 and MRP14 is
mucosal epithelium and involved epidermis in condi-
tions such as psoriasis and malignant disorders [31^
34]. MRP8 and MRP14 are absent in non-di¡erenti-
ated cultured keratinocytes, but are highly expressed
in abnormally di¡erentiated keratinocytes in psoria-
sis [35].
Since the expression of MRP8 and MRP14 ap-
pears to be restricted to speci¢c stages of myeloid
di¡erentiation, the human promyelocytic leukemia
cell line HL-60 was used to study di¡erentiation de-
pendent MRP8 and MRP14 expression (for a review
see [36]). Untreated HL-60 cells express little or none
MRP8 and MRP14 transcripts. Both MRP8 and
MRP14 expression is induced in human HL-60 pro-
myelocytes when the cells di¡erentiate into cells of
monocytic lineage by treatment with 1K,25-dihy-
droxy vitamin D3. Maximal levels of the MRP8
and MRP14 mRNA transcripts are observed be-
tween 2 and 4 days after the treatment. Di¡erentia-
tion of HL-60 along the granulocytic pathway by
DMSO results in enhanced MRP8/14 expression
which corresponds to the high levels of MRP8 and
MRP14 expression observed in human granulocytes
[37,38].
Regulation of gene expression is often associated
with protein binding to the 5P-upstream region.
Therefore, some attempts have been made to locate
the regulatory elements of the MRP8 and MRP14
gene within these regions. One approach is to use
the di¡erentiation-dependent MRP8- and MRP14-
expression of HL-60 cells as indicator for the detec-
tion of speci¢c DNA-binding proteins. Two nuclear
factors were found to bind to the MRP8 and MRP14
genes according to the di¡erentiation of HL-60 cells
into granulocytic cells; one adjacent to the TATA
box and another in the region between 3400 and
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3100. However, neither direct regulatory e¡ects of
these factors nor an identi¢cation of the nuclear fac-
tors has been published [39]. A second study reveals
a novel retinoid responsive element located within
the MRP8 promoter, which is primarily active via
antagonizing the nuclear factor interleukin 6 (NF-
IL6). NF-IL6 is a bZip transcription factor and be-
longs to the CAAT enhancing binding proteins
(C/EBP), indicating that C/EBP is involved in the
expression of the MRP8 and MRP14 genes [40].
Transfection experiments demonstrated that
C/EBP alone is su⁄cient to establish expression of
MRP14 in otherwise negative cells. The upregulation
by C/EBP is antagonized by myb, a transcription
factor active in di¡erentiated myeloid/monocytic cells
[41].
Preliminary results from our laboratory suggest
that the transcriptional activation of MRP8 and
MRP14 genes is regulated di¡erently in monocytic
and granulocytic cells. Di¡erent active DNA ele-
ments are found in both cell types by transfection
analysis. Furthermore, analysis of nuclear proteins,
binding to DNA elements in monocytic or granulo-
cytic cells, reveals di¡erent protein patterns depend-
ing on the cell type. This indicates the complicated
expression machinery involved in regulating the
MRP8 and MRP14 expression, and demonstrates
again the MRP divergence in granulocytes and
monocytes. Besides the very speci¢c action of partic-
ular DNA elements the human MRP14 gene con-
tains a potent enhancer, which is harbored within
intron I of the MRP14 gene [42]. The functional
relevance of that enhancer in MRP8 and MRP14
expression is supported by its conservation in human
and murine MRP at nearly identical positions.
It has been shown that the TPA-induced release of
MRP8 and MRP14 from human monocytes [43] as
well as the ionomycin-induced translocation to cyto-
skeleton and plasma membrane is associated with the
downregulation of de novo synthesis of these pro-
teins at the transcriptional level [44]. The mechanism
responsible for the suppression of MRP8 and
MRP14 mRNA transcription by ionomycin involves
the calcium-induced protein de novo synthesis of a
repressor protein. This suppression is abrogated by
the simultaneous addition of cycloheximide or acti-
nomycin D. In parallel, the MRP8 and MRP14 pro-
tein expression is decreased, and an enhanced MRP8
and MRP14 protein turnover has been excluded [44].
The identi¢cation of suppressor protein and regula-
tory element within the MRP8 and MRP14 gene, to
which the suppressor protein binds, is currently
under investigation in our laboratory.
6. Upon cell activation MRP8/14 heterodimers
translocate to cytoskeleton and cell membrane
MRP8 and MRP14 are predominantly localized in
the cytoplasm. An increase in the intracellular calci-
um concentration leads to a translocation to cyto-
skeletal components and to the plasma membrane
[45]. In contrast to S100K/S100L [46], cysteine resi-
dues of MRP8/14 are not involved in the binding to
cytoskeletal and membrane structures. To elucidate
whether the MRP8/14 heterodimer preferentially
binds via its MRP8 or via its MRP14 subunit to
either membrane or cytoskeleton, transfected L132
cells were studied. MRP8 as well as MRP14 can in-
dependently interact with the cell membrane as well
as with vimentin, thus indicating that association to
these components does not necessarily require
MRP8/14 heterodimer formation [45]. The associa-
tion with vimentin identi¢es these cytoskeletal struc-
tures as type III intermediate ¢laments. The calcium-
dependent reorganization of intermediate ¢laments
plays a prominent role during the activation of
phagocytes [47].
Interestingly, the elevated level of intracellular cal-
cium also leads to the expression of noncovalently
associated MRP8/14 heterodimers on monocytes as
analyzed by £ow cytometry using the MRP8/14 het-
erodimer-speci¢c monoclonal antibody 27E10 [48].
The epitopes on peripheral blood monocytes recog-
nized by the monoclonal antibody 27E10 are present
in acute, but are absent in chronic in£ammatory dis-
orders. Furthermore, the 27E10 surface-positive
monocytes release high amounts of tumor necrosis
factor-K and interleukin-1L in contrast to their
27E10 surface-negative counterparts, thus emphasiz-
ing their role in in£ammation. The mechanism by
which the MRP8/14 heterodimer penetrates the plas-
ma membrane, and how the MRP8/14 protein com-
plex is anchored into the cell membrane, remains
unclear since both proteins lack a transmembrane
region.
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7. MRP8/14 heterodimer is released by a novel
secretory pathway
MRP8 and MRP14 are released as a heterodimer
from 1K,25-dihydroxy vitamin D3-treated HL-60
cells and human monocytes [37,43]. The release of
the MRP8/14 protein complex is induced by the
phorbolester TPA indicating that protein kinase C
is involved in the secretory pathway. This secretory
pathway is distinct from the alternative secretion
pathway as described for interleukin 1 (IL-1). IL-1,
which also lacks a leader sequence or a transmem-
brane region, has been found in small intracellular
vesicles which are shed after monocyte activation
[49]. However, neither endosomes nor vesicles in
the cytosolic fractions contain any MRP8 and
MRP14 as analyzed by electron microscopic tech-
niques [50]. It is demonstrated that both proteins
are secreted by an energy-consuming secretion path-
way which is dependent on an intact microtubule
network and involves the activation of protein kinase
C [43]. Moreover, the secretion of MRP8 and
MRP14 does not necessarily require MRP8/14 cell
surface expression. Therefore, it is suggested that
both surface expression and MRP8/14 heterodimer
secretion may represent two di¡erent, independent
pathways. The presence of MRP8/14 complex in
sera from patients with various in£ammatory condi-
tions including cystic ¢brosis, rheumatoid arthritis,
and sarcoidosis, and the observation of the secretion
of the MRP8/14 complex, may indicate an extra-
cellular role for the MRP8/14 complex.
8. Proposed functions of MRP8 and MRP14
A variety of possible functions for MRP8/14 have
been proposed. MRP8 and MRP14 have been shown
to inhibit casein kinase I and II [51], to interact with
cytoskeletal components [43,45], to exert antimicro-
bial properties, especially against Candida albicans
[52], and to exhibit growth inhibitory activities
against murine bone marrow cells, macrophages,
and mitogen-stimulated lymphocytes [53^55]. The ex-
tended C-terminal tail of MRP14 is suggested to in-
duce neutrophil immobilization, regulation of cyto-
skeletal translocation of the MRP8/14 complex, and
inhibition of the onset of the intrinsic coagulation
cascade [56]. However, the precise function of
MRP8/14, particularly in the extracellular milieu, is
yet unclear.
Human MRP14 has the ability to bind both cal-
cium and zinc ions. Therefore, it has been assumed
that the chelation or sequestration of zinc may cause
the candidastatic e¡ect of MRP14 since zinc has been
shown to be an essential element for bacterial growth
[57]. However, MRP14 also exerts candidastatic ac-
tivity in the presence of zinc-enriched culture me-
dium, and the addition of MRP8 abrogates the in-
hibitory activity [52]. The property to bind zinc may
also have a number of potential functions since zinc
is an essential trace element of eukaryotes (for a re-
view see [58]). Both zinc- and calcium-binding induce
conformational changes leading to the exposure of
hydrophobic surfaces [59], but they bind to di¡erent
binding sites [17]. Thus di¡erent target binding do-
mains may be designed that allow the interaction to
di¡erent target proteins.
8.1. Chemotactic activity
In contrast to human MRP8, murine MRP8 is
shown to have potent chemotactic activity assigned
to the linker region [60^62]. Amino acid sequence
alignment reveals that the calcium binding domains
of murine MRP8 and human MRP8 share 59% ami-
no acid identity, but there is only a weak homology
(21%) within the hinge region and part of the neigh-
boring K-helix joining the calcium-binding domain
(AA42ÿ55). Peptides have been synthesized accord-
ing to the amino acid sequence of equivalent regions
of murine MRP8 and human MRP8. While
mMRP842ÿ55 was some hundredfold less potent
than the full-length mMRP8, the peptide correspond-
ing to hMRP843ÿ56 was inactive in both human and
murine cells, presumably because of predicted di¡er-
ences in the secondary structure [62]. The authors
have suggested that this study con¢rmed the earlier
prediction of Kligman and Hilt [1] that divergence
within the hinge region between members of the fam-
ily may determine functional characteristics. How-
ever, the ¢nding, that murine MRP8 is chemotactic
whereas the human MRP8 is not, leads to the ques-
tion why the function of this protein is limited to one
species. This is in contrast to other ¢ndings where
murine as well as human MRP14 are able to inhibit
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the respiratory burst [63]. Furthermore, murine as
well as human MRP8 and MRP14 speci¢cally bind
polyunsaturated fatty acids in a calcium-dependent
manner (C. Kerkho¡, unpublished observation).
Murine MRP8 and MRP14 are constitutively ex-
pressed in neutrophils, but only the murine MRP8 is
induced in elicited macrophages by LPS [66]. Murine
MRP8 is also expressed in microvascular endothelial
cells after direct stimulation with LPS, IL-1 or tumor
necrosis factor-K [67]. Therefore, mMRP8 released
from activated endothelial cells is suggested to con-
tribute to leukocyte recruitment and leukocyte^endo-
thelial cell interactions thereby exacerbating in£am-
matory responses. The authors suggest that their
hypothesis is further supported by the fact that mur-
ine MRP8-recruited macrophages have a distinct
phenotype; they express high levels of CD11b/
CD18 and scavenger receptors which may play a
major role in atherogenesis and other in£ammatory
responses. However, the suggestion that murine
MRP8 may be involved in exacerbating in£amma-
tory responses is in contrast to an earlier report.
There, it has been described that mMRP8 activates
myeloid cell migration without stimulating the respi-
ratory burst, enzyme release, or calcium ion £ux [68].
Therefore, murine MRP8 is chemoattractant but it
fails to a¡ect neutrophil e¡ector functions. Further
investigations have to elucidate whether mMRP8
may be involved in leukocyte tra⁄cking thereby pro-
moting non-immune leukocyte^endothelial cell inter-
actions, or whether it has a propagating role in in-
£ammatory responses under pathophysiological
situations.
8.2. Stimulation of neutrophil adhesion
Recently, it has been shown that MRP14 exhibits
stimulatory activity on the CD11/CD18 L2 integrins-
mediated adhesion through ligand a⁄nity regulation,
and MRP8 abrogated the MRP14 function, probably
by the formation of the protein complex [69]. The
leukocyte-speci¢c L2 integrins play a pivotal role in
mediating leukocyte adhesion. They are involved
both in speci¢c immune recognition and in several
other non-immune leukocyte^target-cell interactions
(for a review see [70]). The L2 integrin-mediated leu-
kocyte adhesion could be activated (i) by clustering
in the plane of the membrane, (ii) by changes in their
cytoskeletal interactions, (iii) by changes in the num-
ber of integrins expressed at the cell surface, and (iv)
by conformational changes of integrins increasing
their a⁄nity to ligands.
The mechanism of action is suggested to be an
activation from the inside of the cell and not as
one could expect by a direct interaction with L2 in-
tegrins thereby leading to a conformational change.
MRP14 is suggested to bind to a distinct pertussis
toxin-sensitive G-protein-coupled receptor. Unfortu-
nately, the receptor that binds MRP14 has not been
biochemically characterized, and the signal mecha-
nism leading to the conformational change of L2 in-
tegrins needs to be elucidated. The induction of ‘ac-
tivator receptor’ epitopes within the L2 integrin
together with the detection of MRP8/14-positive cells
on endothelial cells at positions, where leukocytes
migrate into tissues, may implicate a function of
MRP14 in stimulating neutrophil adhesion to endo-
thelium either by directly capturing neutrophil adhe-
sion to endothelium or by securing their ¢rm adhe-
sion. In contrast to other chemotactic factors which
also induce neutrophil adhesion, MRP14 fails to mo-
bilize intracellular calcium, to induce exocytosis of
granules, or to stimulate any production of super-
oxides. Thus, the restricted action of MRP14 is sug-
gested to be bene¢cial in minimizing the potential
damage that neutrophils could in£ict on vascular en-
dothelium.
8.3. Cell surface binding site for MRP8/14
Recently, cell surface binding sites speci¢c for the
MRP8/14 complex have been found on human leu-
kemia cells [71]. They have been characterized on
monocytic, T- and B-cell leukemia cell lines, whereas
neither retinoic acid-nor 1K,25-dihydroxy vitamin
D3-treated HL-60 cells express MRP8/14 binding
sites. The number of binding sites on the human
leukemia cells were not a¡ected by retinoic acid or
1K,25-dihydroxy vitamin D3, although these agents
are known to induce di¡erentiation and MRP8 and
MRP14 expression. In addition, cytokines, such as
IL-1 or interferon-Q, fail to change the number of
binding sites. Interestingly, the binding of the
MRP8/14 heterodimer to its binding site is mediated
by MRP8. The further biochemical characterization,
the elucidation of function and signal transduction
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mechanism as well as the identi¢cation of the cell
types which express binding sites for the MRPs will
provide new insights into the molecular basis how
MRP8/14 contribute to the activation and recruit-
ment of e¡ector cells to in£ammatory lesions.
8.4. Calcium-induced binding of polyunsaturated fatty
acids
Recently, two groups independently have shown
that MRP8/14 heterodimers speci¢cally bind fatty
acids in a calcium-dependent manner [64,65]. Binding
and competition studies revealed that oleic, K-lino-
lenic, Q-linolenic, and arachidonic acids are speci¢-
cally bound to the protein complex in a saturable
and reversible manner, whereas saturated fatty acids,
such as palmatic and stearic acids, were poor com-
petitors. The speci¢city towards (poly)unsaturated
fatty acids as well as the reversibility of the binding
to the protein complex excludes the possibility that
merely a solvation of insoluble fatty acid calcium
salts occurs. These results also argue against a coor-
dination of the fatty acid by one of the calcium ions
of the MRP8/14 complex. Both studies di¡er in so
far as the MRP8/14 heterodimer from human kera-
tinocytes binds unsaturated as well as polyunsatu-
rated fatty acids with comparable a⁄nities. In con-
trast, the heterodimer of murine recombinant MRP8
and MRP14 speci¢cally binds arachidonic acid, and
shows only little a⁄nity towards oleic acid (Fig. 3).
The latter was con¢rmed in our laboratory using
native MRP8 and MRP14 from human granulocytes
(C. Kerkho¡, unpublished observation).
The fact that both MRP8 and MRP14 homo-
dimers did not show fatty acid binding leads to the
assumption that docking of the two subunits creates
an asymmetric fatty acid-binding site located at the
interface between the subunits. Both MRP8 and
MRP14 have some post-translational modi¢cations,
and these modi¢cations may in£uence complex for-
mation as well as fatty acid-binding properties. How-
ever, there is no evidence that fatty acid binding is
restricted to some of the isoforms of MRP8/14 het-
erodimers, although several isoforms of the protein
complex may exist. A study dealing with the identi-
¢cation of amino acid residues involved in the bind-
ing of the fatty acid as well as the characterization of
several MRP8/14 heterodimer isoforms and their
fatty acid-binding properties is currently under inves-
tigation in our laboratory.
The calcium-induced binding of polyunsaturated
fatty acids to the MRP8/14 protein complex (Fig.
4) make them a good candidate for mediating e¡ects
of polyunsaturated fatty acids in a calcium-depend-
ent way. Since elevated intracellular calcium levels
induces the release of arachidonic acid from mem-
brane phospholipids by the action of phospholipases
and the expression of arachidonic acid-metabolizing
enzymes (for a review see [72]), the arachidonic acid/
MRP8/14 complex may function as an intermediate
pool or may inhibit the arachidonic acid-metaboliz-
ing enzymes. At a later time point, the MRP8/14
protein complex might pass the ligand to arachidonic
acid-metabolizing enzymes and initiate a delayed ei-
cosanoid formation.
Another link between a member of the S100 pro-
tein family and the cellular lipid metabolism has been
presented by Wu et al. [73]. The protein p11 interacts
with the C-terminus of the 85 kDa cytosolic phos-
pholipase A2 (cPLA2) thereby inhibiting the lipase
activity. The demonstration that the inhibitory activ-
ity of p11 was not due to an interaction of p11 and
the substrate of the lipase leads to the assumption
that the protein^protein interaction induces a confor-
mational change of cPLA2 or an alteration of the
calcium-dependent association of cPLA2 with the
membrane substrate. However, it has not been tested
whether p11 binds fatty acids. Further investigations
have to elucidate the role of p11 in the cPLA2-medi-
ated release of arachidonic acid.
9. Conclusions and future perspectives
In areas of acute in£ammation polymorphonuclear
leukocytes (PMN), expressing the membrane-associ-
ated heterodimer MRP8/14, are the predominant cell
type. These cells have been shown to release high
amounts of TNF-K and IL-1L, indicating that
27E10 antigen expression is restricted to activated
or recruited phagocytes [11]. The 27E10 antigen-ex-
pressing cells are present in acute but absent in
chronic in£ammatory disorders [48]. These ¢ndings,
together with the elevated plasma levels of MRP8/14
in patients with chronic diseases such as rheumatoid
arthritis and neurodermatitis [12,13], has led to the
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assumption that MRP8 and MRP14 a¡ect leukocyte
tra⁄cking and display a propagating role in in£am-
matory responses.
Recent investigations give insights by which mech-
anism MRP8 and MRP14 promote leukocyte^endo-
thelial cell interaction. It has been shown that
MRP14 induces neutrophil adhesion through control
of L2 integrin Mac-1 activity, and MRP14 fails to
a¡ect neutrophil e¡ector functions, such as exocyto-
sis of granules and production of superoxides. MRP8
has a regulatory role on MRP14 activity by inhibit-
ing the MRP14-induced adhesion through the forma-
tion of the heterodimer [69]. However, the study fails
to identify the cell type from which MRP14 is inde-
pendently released from MRP8. To date, the secre-
tion of MRP8/14 heterodimer has only been reported
from monocytes [43], although it has been speculated
that epithelial cells also actively secrete MRP8/14
[74]. Mariano and co-workers have identi¢ed
MRP14 as a macrophage-deactivating factor that is
released by epithelioid macrophages and inhibits the
respiratory burst of mycobacterial-activated macro-
phages [63]. The ¢nding that MRP8/14 heterodimers
speci¢cally bind the eicosanoid precursor arachidonic
acid [64,65] represents another cellular mechanism by
which MRP8 and MRP14 may a¡ect leukocyte ad-
hesion. Eicosanoids have been shown to play a reg-
ulatory role in in£ammatory responses. For example,
15-HETE has been shown to be a potent endogenous
inhibitor of PMN-endothelial interactions in vivo
[75,76], and leukotriene B4 is a potent chemoattrac-
tant [77]. The formation of an intermediate intracel-
lular pool of arachidonic acid/MRP8/14 may a¡ect
the arachidonic acid-metabolizing enzymes by sub-
strate supply. It has been proposed that MRP8/14
may suppress the formation of eicosanoids. A regu-
latory role of the intracellular fatty acid/fatty acid-
binding protein pool in conjunction with fatty acid-
consuming cellular processes has been demonstrated
for phospholipid, triacylglycerol, and cholesterol es-
ter synthesizing pathways [78^80]. At a later time
point, the MRP8/14 protein complex may pass the
ligand to arachidonic acid-metabolizing enzymes and
initiate a delayed eicosanoid formation. Taken to-
gether, these studies show that MRP8 and MRP14
play a role in leukocyte tra⁄cking, but do not a¡ect
neutrophil e¡ector functions. Whether these actions
are bene¢cial, in terms of minimizing the potential
damage which neutrophils could in£ict on vascular
endothelium or propagate the in£ammatory response
in concert with chemotactic mediators and leukocyte
activation, remains to be elucidated.
Fig. 3. Binding of arachidonic and oleic acids to recombinant
murine MRP8 and MRP14. The heterodimer MRP8/14 binds
arachidonic acid signi¢cantly, whereas the interaction of mono-
mers and homodimers is negligible. Binding of arachidonic acid
to the MRP8/14 complex was absent in the presence of EDTA.
Control experiments using oleic acid resulted only in minor
binding. For experimental details see Klempt et al. [64].
Fig. 4. Binding of arachidonic acid to human MRP8/14 com-
plex depends on the Ca2-concentration. The fatty acid is
bound in a saturable and reversible manner to the protein com-
plex, and the binding is saturated at 100 Wmol/l calcium. For
experimental details see Klempt et al. [64].
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The extracellular role for MRP14 is interweaved
with the release of MRP8 and MRP14 by an active
mechanism of secretion and the existence of cell sur-
face binding sites speci¢c for MRP8 and MRP14.
Recently identi¢ed cell surface binding sites found
on human leukemia cells bind the MRP8/14 hetero-
dimer via the MRP8 subunit [71]. Newton and Hogg
[69] have characterized a MRP14 binding site that
represents a pertussis toxin-sensitive G-protein-
coupled receptor. However, Mariano’s group [63]
have so far not succeeded in their search for the
mechanism by which MRP14 inhibits the respiratory
burst. Therefore, further investigations have to pin-
point the binding sites and the cells expressing the
putative receptor. A novel role for MRP14 as a reg-
ulatory molecule of macrophage adhesion and acti-
vation will provide new insights into the understand-
ing of in£ammatory mechanisms.
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